Barry added: "Our anti-HIV drug MKC-442 has advanced into Phase Ib/IIa trials, and we are also beginning to recruit patients for a Phase II pilot efficacy trial of alanosine
in glioma and non-small cell lung cancer.
For example, CS-92, a nucleoside reverse transcriptase inhibitor, is in Phase I/II studies for the treatment of HIV infection, and alanosine
is in Phase II pilot studies for the treatment of brain and lung cancers.
In addition, we opened enrollment under an Investigator IND held by the University of California, San Diego for Phase II studies of our anti-cancer compound, alanosine
, in patients with non-small cell lung cancer or glioma.